What's New


License Agreement for Research Use Field Has Been Entered with NeuCyte, Inc.

We executed a non-exclusive license agreement with NeuCyte, Inc., a biopharmaceutical company with a focus on neurological diseases, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.

NeuCyte provides iPS cell derived neural cells and related services for research use related to CNS drug discovery and pre-clinical drug neurotoxicity and safety assessment.

Back to top